Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuron Ltd ADR
(NQ:
IMRN
)
1.952
+0.032 (+1.66%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immuron Ltd ADR
< Previous
1
2
Next >
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
October 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Travelan® continued strong sales growth
October 15, 2024
From
Immuron Limited
Via
GlobeNewswire
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
October 04, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
August 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
August 15, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
August 07, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron announces record Travelan® sales globally, Australia and USA
July 15, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing
July 02, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
June 05, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Board Changes
May 31, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore to present at Peak Sky High
May 31, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Limited to Present at the Emerging Growth Conference
May 07, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Director Resignation
May 03, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron to host Live Virtual Event
April 15, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Travelan® sales continued strong growth
April 10, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
March 07, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record Travelan® sales
February 13, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
February 08, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record half yearly Travelan® sales
January 16, 2024
From
Immuron Limited
Via
GlobeNewswire
Immuron Clinical Trials Update
December 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
December 04, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record quarterly Travelan® sales
October 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron hails record monthly sales of Travelan
September 14, 2023
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®....
Via
TheNewswire.com
Immuron achieves record monthly Travelan® sales
September 13, 2023
From
Immuron Limited
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
